A clinician's guide to ADHD treatment options.

Area of Science:

• Neurodevelopmental disorders
• Pediatric medicine
• Pharmacology

Background:

• Attention deficit/hyperactivity disorder (ADHD) is a prevalent neurodevelopmental condition affecting children, adolescents, and adults.
• Primary care physicians often serve as the initial point of contact for ADHD diagnosis and treatment.
• Psychostimulant therapy is a recommended first-line treatment for ADHD due to its efficacy in symptom management.

Purpose of the Study:

• To provide physicians with a resource for selecting appropriate stimulant formulations for ADHD patients.
• To review available and emerging methylphenidate and amphetamine formulations.
• To address challenges in medication adherence and administration for diverse patient needs.

Main Methods:

• Literature review of current psychostimulant formulations for ADHD.
• Analysis of various dosage forms, including liquid, chewable, capsules, patches, and orally disintegrating tablets.
• Discussion of formulations in development for future ADHD treatment.

Main Results:

• A wide array of methylphenidate and amphetamine formulations are available to suit individual patient lifestyles and preferences.
• Novel delivery systems address challenges for patients with difficulty swallowing or adherence issues.
• Emerging formulations promise further customization in ADHD pharmacotherapy.

Conclusions:

• The variety of available stimulant formulations enhances the management of ADHD across different patient populations.
• Physicians can utilize this information to personalize ADHD treatment plans effectively.
• Continued innovation in formulation development is crucial for optimizing ADHD care.